Despite their prevalence and detrimental impact on patients, RINV are underestimated and undertreated by radiation oncologists,[2–5,7] and a limited amount of research into RINV exists compared with the extensive investigations that have been undertaken for CINV. The remainder of this article will present themes related to RINV clinical management and research, and highlight the factors and challenges that are preventing progress in this field. It will also provide solutions to these challenges for clinicians and investigators.
Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(6):685-692. © 2011 Expert Reviews Ltd.